III期研究-话题@MedSci

#III期研究#

101篇内容 | 2917人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021391, encodeId=d45d2021391dd, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, objectType=article, longId=213341, objectId=9b0321334101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0321334101, replyNumber=0, likeNumber=77, createdTime=2022-01-18, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0321334101, moduleTitle=Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0321334101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021392, encodeId=9f84202139229, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽, objectType=article, longId=213588, objectId=8938213588ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8938213588ec, replyNumber=0, likeNumber=81, createdTime=2021-10-24, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8938213588ec, moduleTitle=NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8938213588ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021394, encodeId=43d52021394b7, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, objectType=article, longId=215670, objectId=64082156e056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64082156e056, replyNumber=0, likeNumber=73, createdTime=2021-12-23, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64082156e056, moduleTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64082156e056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021382, encodeId=8368202138273, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=0, createdTime=2021-02-28, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, objectType=article, longId=203284, objectId=ffda20328428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffda20328428, replyNumber=0, likeNumber=118, createdTime=2020-11-28, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffda20328428, moduleTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffda20328428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021380, encodeId=76d82021380fb, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=66, createdTime=2021-03-06, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021389, encodeId=8b8e20213892e, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果, objectType=article, longId=212452, objectId=42a3212452e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42a3212452e6, replyNumber=0, likeNumber=85, createdTime=2022-05-16, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42a3212452e6, moduleTitle=J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42a3212452e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021372, encodeId=c44120213e2b2, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, objectType=article, longId=199330, objectId=176519933069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176519933069, replyNumber=0, likeNumber=64, createdTime=2021-04-10, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176519933069, moduleTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176519933069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021370, encodeId=1c7c20213e06f, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=58, createdTime=2020-09-24, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021377, encodeId=b84420213e777, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, objectType=article, longId=202989, objectId=b8be20298966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8be20298966, replyNumber=0, likeNumber=81, createdTime=2020-11-13, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8be20298966, moduleTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8be20298966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021387, encodeId=5a1c202138efe, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=中重度斑块型银屑病治疗药物依奇珠单抗临床III期研究(RHBH)中国人群取得积极主要研究结果, objectType=article, longId=210549, objectId=10c5210549d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10c5210549d6, replyNumber=0, likeNumber=57, createdTime=2021-11-17, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10c5210549d6, moduleTitle=中重度斑块型银屑病治疗药物依奇珠单抗临床III期研究(RHBH)中国人群取得积极主要研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10c5210549d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021374, encodeId=58cc20213e480, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展, objectType=article, longId=202039, objectId=6aa0202039eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa0202039eb, replyNumber=0, likeNumber=76, createdTime=2021-09-23, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa0202039eb, moduleTitle=Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa0202039eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021378, encodeId=086020213e816, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, objectType=article, longId=203133, objectId=529b20313392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529b20313392, replyNumber=0, likeNumber=67, createdTime=2020-11-30, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529b20313392, moduleTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=529b20313392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021367, encodeId=4323202136e93, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=失眠新药daridorexant的全新III期研究数据, objectType=article, longId=197166, objectId=4ec319e1668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ec319e1668c, replyNumber=0, likeNumber=133, createdTime=2020-07-06, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ec319e1668c, moduleTitle=失眠新药daridorexant的全新III期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ec319e1668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021375, encodeId=c37f20213e571, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡, objectType=article, longId=202184, objectId=2910202184d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2910202184d2, replyNumber=0, likeNumber=68, createdTime=2021-08-03, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2910202184d2, moduleTitle=基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2910202184d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021363, encodeId=8af4202136361, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), objectType=article, longId=193163, objectId=3f4219316311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4219316311, replyNumber=0, likeNumber=66, createdTime=2021-01-30, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4219316311, moduleTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4219316311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021373, encodeId=f42320213e3ce, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, objectType=article, longId=201031, objectId=6a33201031d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a33201031d1, replyNumber=0, likeNumber=85, createdTime=2021-02-19, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a33201031d1, moduleTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a33201031d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021385, encodeId=7db92021385aa, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=吸入型ZYESAMI治疗重症COVID-19，即将开展II/III期研究, objectType=article, longId=206766, objectId=4d07206e6625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d07206e6625, replyNumber=0, likeNumber=81, createdTime=2021-10-29, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d07206e6625, moduleTitle=吸入型ZYESAMI治疗重症COVID-19，即将开展II/III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d07206e6625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021371, encodeId=062e20213e157, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, objectType=article, longId=197637, objectId=bcef19e637ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcef19e637ac, replyNumber=0, likeNumber=74, createdTime=2020-10-26, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcef19e637ac, moduleTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcef19e637ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021376, encodeId=3de420213e63c, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, objectType=article, longId=202883, objectId=f95120288352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95120288352, replyNumber=0, likeNumber=69, createdTime=2021-09-22, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95120288352, moduleTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f95120288352)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期研究

2020-05-29

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Ann Oncol: MIRV对比研究者选择的化疗在铂耐药上皮性卵巢癌(EOC)患者中的疗效和安全性: III期研究FORWARD I的初次分析结果

2022-01-18

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

NEJM：Tirzepatide头对头III期研究成功降糖减重效果优于索马鲁肽

2021-10-24

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析

2021-12-23

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-02-28

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点

2020-11-28

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2021-03-06

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

J Headache Pain：依普奈珠单抗预防慢性偏头痛的有效性和安全性：PROMISE-2 III期研究结果

2022-05-16

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准

2021-04-10

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-09-24

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎

2020-11-13

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

中重度斑块型银屑病治疗药物依奇珠单抗临床III期研究(RHBH)中国人群取得积极主要研究结果

2021-11-17

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展

2021-09-23

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果

2020-11-30

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

失眠新药daridorexant的全新III期研究数据

2020-07-06

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡

2021-08-03

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)

2021-01-30

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相

2021-02-19

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

吸入型ZYESAMI治疗重症COVID-19，即将开展II/III期研究

2021-10-29

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%

2020-10-26

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市

2021-09-22

科室
- - 订阅+
  - 更多科室
工具
服务